Kira6 is primarily used in research settings as a selective inhibitor of the IRE1α pathway, which is part of the unfolded protein response (UPR) in cells. It helps modulate cellular stress responses, particularly in conditions where protein misfolding occurs, such as in neurodegenerative diseases, diabetes, and certain cancers. By inhibiting IRE1α’s RNase activity, Kira6 reduces the production of spliced XBP1, a transcription factor involved in inflammation and cell survival. This makes it a valuable tool for studying diseases linked to endoplasmic reticulum stress. It has shown potential in preclinical models for protecting pancreatic beta cells, reducing tumor growth, and mitigating inflammatory responses. Its application is mainly focused on therapeutic development and mechanistic studies in cellular stress pathways.